Clinical trials for Sarcoma and GIST

99 currently recruiting clinical trials
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Stomach and esophageal cancer Sarcoma and GIST #NCT05152472 #2022-503068-34-00
Required histologic types
GIST
Required histologic sub types
Gastrointestinal stromal tumor
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy
11 recruiting sites
Centre Léon Bérard
Phase 2 Stomach and esophageal cancer Sarcoma and GIST #NCT05009927 #2024-512631-77-00
Required histologic types
GIST
Required histologic sub types
Gastrointestinal stromal tumor
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KIT
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Centre Léon Bérard
Phase 2 Sarcoma and GIST #NCT03548428 #2024-511313-38-00
Required histologic types
Soft tissue sarcoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None 1
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
Centre Antoine Lacassagne
Phase 2 Sarcoma and GIST #NCT06022159
Required histologic types
Soft tissue sarcoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy
11 recruiting sites
Institut Claudius Regaud
Phase 2 Sarcoma and GIST #NCT04698785
Required histologic types
Bone sarcoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
8 recruiting sites
Centre Léon Bérard
Phase 2 Pancreas cancer Sarcoma and GIST #NCT05732831 #2022-502645-99-00
Required histologic types
Bone sarcoma Soft tissue sarcoma
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
MTAP
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Tango Therapeutics
Phase 1 / Phase 2 Sarcoma and GIST #NCT07602777 #2025-523997-18-00
Required histologic types
Bone sarcoma Soft tissue sarcoma
Required histologic sub types
Osteosarcoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
GlaxoSmithKline
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07288359 #2025-521911-38-00
Phase I autres tumeurs avec amplification du gène CCNE1
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Novartis
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT07397338 #2025-524623-50-00
Cohorte Tumeur solide /CRC (bras C pour l'expansion de dose de la partie 2)
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS RAS
Required number of previous lines of therapy
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Revolution Medicines, Inc.